rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. rezolute is advancing a diversified pipeline including: rz358 (phase 2), an antibody for the ultra-orphan indication of congenital hyperinsulinism (chi) with an abbreviated path-to-market strategy; ab101 (phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and rz402 (plan to file ind in h2 2018), a plasma kallikrein inhibitor (pki) targeting diabetic macular edema (dme). for more information, visit: www.rezolutebio.com.
Company profile
Ticker
RZLT
Exchange
Website
CEO
Nevan Elam
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AntriaBio, Inc., FITS MY STYLE INC
SEC CIK
Corporate docs
Subsidiaries
Rezolute Bio UK, Ltd • Rezolute (Bio) Ireland Limited ...
RZLT stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
12 Apr 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Other Events
22 Feb 24
10-Q
2024 Q2
Quarterly report
13 Feb 24
8-K
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
13 Feb 24
8-K
Unregistered Sales of Equity Securities
29 Jan 24
8-K
Plans to report topline data mid-second quarter 2024
14 Dec 23
EFFECT
Notice of effectiveness
30 Nov 23
CORRESP
Correspondence with SEC
27 Nov 23
Latest ownership filings
4
BRIAN KENNETH ROBERTS
29 Mar 24
4
Change in insider ownership
19 Mar 24
4
Daron Evans
19 Mar 24
4
BRIAN KENNETH ROBERTS
18 Mar 24
4/A
BRIAN KENNETH ROBERTS
18 Mar 24
4
Young-Jin Kim
14 Mar 24
SC 13G
Nantahala Capital Management, LLC
11 Mar 24
4
BRIAN KENNETH ROBERTS
11 Mar 24
4
Daron Evans
8 Mar 24
4
Nevan C Elam
28 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.06 mm | 8.06 mm | 8.06 mm | 8.06 mm | 8.06 mm | 8.06 mm |
Cash burn (monthly) | 2.66 mm | 12.19 mm | 5.30 mm | 5.14 mm | 3.53 mm | 3.96 mm |
Cash used (since last report) | 18.18 mm | 83.32 mm | 36.26 mm | 35.14 mm | 24.12 mm | 27.06 mm |
Cash remaining | -10.12 mm | -75.27 mm | -28.21 mm | -27.08 mm | -16.06 mm | -19.00 mm |
Runway (months of cash) | -3.8 | -6.2 | -5.3 | -5.3 | -4.6 | -4.8 |
Institutional ownership, Q2 2023
60.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 2 |
Closed positions | 6 |
Increased positions | 7 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 47.92 bn |
Total shares | 24.22 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FHI Federated Hermes Inc - Ordinary Shares | 6.61 mm | $13.09 bn |
First Manhattan | 3.62 mm | $7.17 bn |
Stonepine Capital Management | 3.07 mm | $6.08 bn |
BX Blackstone | 1.54 mm | $3.04 bn |
Vanguard | 1.41 mm | $2.79 bn |
Caxton | 1.32 mm | $2.61 bn |
Sphera Funds Management | 1.16 mm | $2.29 bn |
Nantahala Capital Management | 769.61 k | $1.52 bn |
Adage Capital Partners GP, L.L.C. | 631.69 k | $1.25 bn |
CVI | 584.03 k | $1.16 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Brian Kenneth Roberts | Common Shares | Buy | Acquire P | Yes | No | 2.55 | 500 | 1.28 k | 1,076 |
15 Mar 24 | Evans Daron | Common Shares | Buy | Acquire P | Yes | No | 1.6915 | 20,000 | 33.83 k | 20,000 |
14 Mar 24 | Brian Kenneth Roberts | Common Shares | Buy | Acquire P | Yes | No | 1.88 | 10,000 | 18.80 k | 10,000 |
8 Mar 24 | Evans Daron | Common Shares | Buy | Acquire P | No | No | 1.9269 | 50,000 | 96.35 k | 120,900 |
7 Mar 24 | Brian Kenneth Roberts | Common Shares | Buy | Acquire P | Yes | No | 1.85 | 500 | 925.00 | 500 |
News
JMP Securities Reiterates Market Outperform on Rezolute, Maintains $7 Price Target
19 Apr 24
JMP Securities Reiterates Market Outperform on Rezolute, Maintains $7 Price Target
18 Apr 24
JonesTrading Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $10
18 Apr 24
Maxim Group Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $8
9 Apr 24
$1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
11 Mar 24